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Open Forum Infectious Diseases
PERSPECTIVES

The Hospital Antimicrobial Use Process: From Beginning
to End
William R. Truong1 and Jason Yamaki2,3
1

Department of Pharmacy, St. Joseph Hospital, Orange, California; 2Department of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, California; and 3Department of Pharmacy,
Hoag Memorial Hospital Presbyterian, Newport Beach, California

Hospital antimicrobial stewardship (AMS) programs are responsible for ensuring that all antimicrobials are utilized in the most
appropriate and safe manner to improve patient outcomes, prevent adverse drug reactions, and prevent the development of antimicrobial resistance. This Perspectives article outlines the hospital antimicrobial use process (AUP), the foundational system that
ensures that all antimicrobials are utilized in the most appropriate and safe manner. The AUP consists of the following steps: antimicrobial ordering, order verification, preparation and delivery, administration, monitoring, and discharge prescribing. AMS
programs should determine how each step contributes to how an antimicrobial is used appropriately or inappropriately at their
institution. Through this understanding, AMS programs can integrate stewardship activities at each step to ensure that every opportunity is taken to optimize antimicrobial use during a patient’s treatment course. Hence, approaching AMS through the framework
of a hospital’s AUP is essential to improving appropriate antimicrobial use.
Keywords. antibiotics; antimicrobial resistance; antibiotic stewardship; antimicrobial stewardship program; antimicrobial use
process.
Antimicrobial stewardship (AMS) is predicated on ensuring
appropriate and optimal antimicrobial use to improve patient
outcomes, prevent adverse drug reactions, and prevent the
development of antimicrobial resistance [1, 2]. Although there
is no universal definition of appropriate antimicrobial use,
expert societies consider the “selection of the optimal antimicrobial drug regimen including dosing, duration of therapy,
and route of administration” as an indicator of appropriate use
[3]. Hospital-based AMS programs are tasked with developing,
implementing, and monitoring interventions to meet the goal of
improving appropriate antimicrobial use. As AMS is by virtue
an endeavor to improve pharmaceutical drug use in patients,
stewards need to appreciate and approach AMS within the
framework of their hospital’s antimicrobial use process (AUP)
to comprehensively integrate effective stewardship practices.
The AUP is the foundational system that ensures all antimicrobials are utilized in the most appropriate and safe manner across
all settings. Despite being a foundational element for appropriate antimicrobial usage, it may not be thoroughly reviewed as
a whole by specifically looking at each step of the process and
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how it relates to antimicrobial usage, and how each step can be
improved. The AUP is based broadly on the medication use process, which traditionally consists of 5 principal steps: prescribing,
transcribing, dispensing, administration, and monitoring [4].
The AUP within the context of a hospital can be adapted to
include the following steps: antimicrobial ordering, order verification, preparation and delivery, administration, monitoring,
and discharge prescribing (Figure 1). Optimal execution of
each step ensures that the patient receives the right drug, at the
right dose, at the right time, for the right duration, and with the
narrowest spectrum of activity required to treat the infection.
Therefore, AMS practices and processes need to be integrated at
each of these steps to ensure this outcome. This can be achieved
by having a holistic understanding of the antimicrobial use
process. In this article, each step of the AUP is presented, their
importance is explained, and examples of AMS activities are
given that occur at each step to optimize the process.
PRESCRIBER ORDERING

Prescribing of antimicrobials during physician order entry
is the first step of the AUP, and for this reason, it is a critical
focus of AMS interventions as it is ideal to have the optimal
antimicrobial entered at the beginning of the process. In hospitals that utilize computerized physician order entry systems,
electronic behavioral change interventions have been shown
to be effective in driving appropriate antimicrobial use [5, 6].
Implementation of antimicrobial order sets that incorporate
syndrome-specific clinical pathways to “guide” prescribers
toward guideline-concordant and institutional best practice
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Diagram of the antimicrobial use process and the possible health care professionals who are involved at each step.

therapy are widely used by AMS programs to improve antimicrobial use [7–9]. Best practice alerts (ie, “pop-ups”) utilizing clinical decision support mechanisms can be used to notify
prescribers of which agents may or may not be appropriate
based on computed clinical data, local susceptibilities, hospital formulary, and restriction criteria. Requiring the prescriber
to input a clinical indication during electronic order entry has
also been shown to be effective in reducing antimicrobial use in
the outpatient setting and can be used in the inpatient setting
to promote judicious use [10]. In institutions that lack robust
electronic medical record (EMR) capabilities where best practice alerts, computerized order entry, and order sets cannot be
utilized, hard copy best practice and institutional guidelines
that are easily accessible can provide guidance to prescribers
during order entry [1].
PHARMACIST ORDER VERIFICATION

An important juncture in the AUP is the step following prescriber ordering: pharmacist order verification. During this
step, the prescriber has already entered an order for a patient
and requires verification by a pharmacist. Order verification
pharmacists are responsible for ensuring that drug interactions and allergies are assessed, dosing is adjusted for organ
dysfunction, and duplications of therapy are reconciled.
Many hospitals have pharmacist-driven automatic renal dosing protocols that allow for timely adjustment of dosing [11].
Duplications in therapy (eg, double beta-lactam or double
anaerobic coverage) ideally should be intervened on at this
stage by contacting the prescriber to inquire about the need
for duplication. In institutions that utilize pharmacist-driven
pharmacokinetic dosing protocols, the pharmacist at this step
is typically responsible for initiating the dosing and monitoring of vancomycin and/or aminoglycosides to ensure attainment of target serum concentrations to optimize efficacy and
reduce toxicity [12–14]. In hospitals where preauthorization
of restricted antimicrobials is required for ordering, order verification pharmacists ensure that each restricted agent has met
the hospital’s policy for use [15].
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PREPARATION AND DELIVERY

Once an antimicrobial order is verified and processed by the
order verification pharmacist, pharmacy personnel are tasked
with the preparation and compounding of each drug. Accurate
preparation and timely delivery of the antimicrobial to the
patient’s unit is critical for the treatment of severe infections
manifesting in sepsis. As studies have demonstrated increasing mortality when time elapses to the first administration of
broad-spectrum antimicrobials [16, 17], pharmacy workflow
and delivery methods need to be optimized to ensure that the
time between drug preparation and delivery to the patient’s unit
is reduced. Additionally, accurate preparation is necessary to
ensure that the patient receives the correct dose and a product
that is safe for use. The clinical ramifications of accurate and
safe preparation are emphasized by adverse events and deaths
that have occurred with compounded medications. According
to Pew Charitable Trusts, during the period of 2001–2017, there
were 1416 adverse events and 115 deaths associated with compounded or repackaged medications [18]. Automated drug
dispensing cabinets containing premixed antibiotics in patient
care units have been shown to reduce time to intravenous antibiotic administration [19]. Also important is the need to educate pharmacy technicians on the importance of their role in
the AUP and how their compounding and delivery efforts have
an impact on patient care. Lastly, considered a “low-hanging
fruit” intervention, antimicrobial batching during preparation
is a method employed at this step to reduce waste and expenditures for certain high-cost drugs such as daptomycin and caspofungin [20].
ADMINISTRATION

Antimicrobial administration is performed by bedside nurses,
and hence nursing serves a critical role in the AUP [21, 22].
Timely antimicrobial administration is a crucial factor during
this step, and nurses should accurately record the dose and time
of each administration. Precise administration at scheduled
frequency intervals ensures that consistent serum drug concentration levels are achieved. If cultures are ordered, every effort

should be made to administer the antibiotics after cultures
are taken, so long as it does not extensively prolong the time
to antibiotic administration. This ensures optimal microbiological yield of each culture, which provides critical organism
identification and susceptibility information during the treatment course. In hospitals where extended infusion beta-lactam
administration is utilized, nurses are responsible for ensuring
that these antibiotics are programmed to be administered at the
correct infusion duration and that any residual antibiotic in the
intravenous lines is infused into the patient. Furthermore, coordinating the administration of vancomycin or aminoglycosides
relative to serum level draws prevents any aberrated serum level
results, potentially leading to suboptimal therapy. Ensuring
compatibility of intravenous antibiotics with other drugs during infusion is also important to maximize therapeutic effect
and avoid adverse events.
MONITORING

Antimicrobials should be monitored for efficacy and toxicity daily.
Certain interventions can be implemented at this stage to ensure
that antimicrobials are appropriately managed. One intervention outlined in the Centers for Disease Control and Prevention’s
(CDC’s) Core Elements of Hospital Antibiotic Stewardship
Programs, and now required by The Joint Commission as an
accreditation standard, is implementation of an antibiotic timeout. An antibiotic timeout requires the treating team to assess their
patient’s antibiotics 48 hours after they are initiated to determine
if they still need to be continued or if any adjustments need to be
made [2]. After 48 hours, more diagnostic and microbiological
data (ie, culture results) are available to guide the treating team in
modifying antibiotics (eg, de-escalation). If technologically feasible, computerized best practice alerts can be utilized to notify the
prescriber that a timeout assessment is due and acknowledge that
an assessment has been conducted. Institutions utilizing pharmacist-driven timeout assessments have demonstrated improved
antibiotic use [23, 24]. Bedside nurses, as central communicators
throughout an inpatient stay, can also be involved in the timeout
process by prompting the treating team to assess antimicrobials
and duration of therapy.
A principal component of monitoring that should be performed is daily prospective audit and feedback. This is conducted by a clinical infectious diseases pharmacist or physician
and is one of the core activities undertaken by an antimicrobial
stewardship program [25–27]. Hospitals can invest in pharmacosurveillance and data-mining software applications to
readily identify patient cases that are candidates for stewardship interventions. This allows the stewardship team to review
and provide interventions on an expanded scope of patients
as identification of intervention opportunities is automated
[28]. Alternatively, if these software applications are not available, manual antimicrobial reports can be generated to identify
patient cases for stewardship interventions.

Additionally, during this stage of the AUP, patient-level
assessments should occur through labs and physical examination to monitor for development of adverse drug reactions. For
example, physicians and nurses should monitor for cutaneous
reactions and/or diarrhea to determine if there are any signs of
hypersensitivity reaction or possible Clostridium difficile infection among other medication-specific monitoring parameters.
Furthermore, the treating and antimicrobial stewardship team
should identify patients who are candidates for intravenous to
oral conversion and intervene to switch the patient to oral therapy [29]. The CDC recommends that hospitals have in place
intravenous-to-oral antimicrobial conversion programs where
conversion is done automatically, typically by a clinical pharmacist, when the patient meets specified inclusion and exclusion
criteria [2]. Good communication between clinicians is critical
in institutions that utilize rapid diagnostics. Rapid diagnostics
are only beneficial if results are rapidly translated into appropriate modifications of the patient’s antimicrobial regimen. In many
institutions, critical culture results, whether obtained via rapid
diagnostics or traditional culture methods, are communicated
from the microbiology laboratory to the bedside nurse, who
then communicates them to the physician. This process must be
made efficient to ensure that the patient benefits from a rapid
diagnostic result. Alternative approaches have also included
notification directly to the team physician, as well as the patient’s
nurse. In some institutions, results of rapid cultures are provided
to a clinical pharmacist, who then communicates the information to the physician with a recommendation for therapy modification [30]. The mechanism by which the physician is notified
will depend on the resources available at the institution.
DISCHARGE PRESCRIBING

The final step in the AUP is the prescribing of antimicrobials
for the transition from inpatient to outpatient. Once patients
are clinically stable, they often are discharged on oral stepdown antimicrobials to complete their treatment course [31].
When this occurs, it is typically with an outpatient prescription,
and at many hospitals, it may not be prescribed through the
computerized physician order entry system. Therefore, these
antimicrobial prescriptions may not be subjected to the stewardship oversight and detailing described in the earlier AUP
stages. This is an important gap as oral step-down therapy often
involves a different class of antimicrobial (ie, beta-lactam to
fluoroquinolone) or a different agent within the same class (ie,
cefazolin to cephalexin). Hence, spectrum of activity, dosing,
contraindications, hypersensitivity potential, and pharmacokinetic/pharmacodynamic properties may be different than the
inpatient intravenous antimicrobial that a patient was receiving. This can lead to inappropriate antimicrobial prescribing at
patient discharge [31, 32].
Discharge oral prescriptions are typically filled at outside
pharmacies, which do not have access to the patient’s hospital
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Figure 2. A scenario in which a patient with an intra-abdominal infection, without Clostridium difficile infection, is unnecessarily prescribed double anaerobic coverage
with piperacillin-tazobactam and metronidazole while hospitalized. This Swiss cheese model depicts a series of failures within the antimicrobial use process ultimately
resulting in discharge prescribing of double anaerobic coverage for the entire treatment course. Abbreviations: AMS, antimicrobial stewardship; CDS, clinical decision
support; TOC, transitions of care.

medical record or details on their inpatient clinical course.
Furthermore, patients may be discharged when cultures are
preliminary, and final results may not be available until after
the patient leaves the hospital, potentially leaving the patient on
inappropriate therapy (eg, resistant organism) [33]. Discharge
prescribing is an important step in the AUP that stewardship
programs can intervene on. Reviewing discharge prescriptions
for appropriateness and their duration of therapy can ensure
that the patient completes their therapy on the right drug, at the
right dose, for the right duration, and one with the narrowest
spectrum of activity. Hospitals can implement transition of care
programs that consist of a coordinated team of pharmacists,
physicians, nurses, and care coordinators to improve the patient
discharge process. Transition of care pharmacists can be integral
members of AMS programs by providing stewardship services
during the discharge prescribing process as well as conducting
medication reconciliation and reviews, and counseling patients
on newly initiated medications. For patients being discharged
on intravenous antibiotics, an outpatient parenteral antimicrobial therapy (OPAT) program can improve patient outcomes by
reducing hospital readmissions [34].
Postdischarge antimicrobial therapy is often prolonged or
may not be warranted at all. Thus, it is important at discharge
planning to account for the number of days of effective antimicrobial therapy that a patient has already received in the
hospital to avoid excess duration of total therapy. For patients
being discharged to a skilled nursing or long-term care facility,
documenting the duration of therapy is critical to ensuring that
antimicrobials are discontinued on the appropriate date [35]. In
some cases, the patient may have completed an adequate course
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of antimicrobial therapy, and utilizing their clinical response
and biomarkers such as procalcitonin, discontinuation of therapy may be considered. This approach, particularly with the
use of procalcitonin levels and other clinical parameters, would
require education of clinicians, but there has been reported success in decreasing antimicrobial use with this approach [36, 37].
CONCLUSIONS

Various AMS activities and processes may lead to positive outcomes and occur at different steps of a continuum that can be
termed the antimicrobial use process. Understanding all steps
of the AUP from beginning to end will allow for institutions to
better integrate AMS activities within the AUP. This integration
reduces the opportunity for an inappropriate antimicrobial to be
administered to a patient, and if administered, downstream AUP
stewardship systems should identify and rectify the situation as
soon as possible. Additionally, in the event that an inappropriate
antimicrobial is administered to the patient, AMS programs can
conduct a root cause analysis to identify the AUP stage in which
it occurred and factors that allowed the inappropriate antimicrobial to proceed through and reach the patient (Figure 2).
Conducting this analysis will provide insights on how to improve
the AUP to prevent future inappropriate antimicrobial use. By
understanding and optimizing a hospital’s AUP, AMS programs
can prevent or reduce inappropriate antimicrobial use.
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